Harada, Ryoko
Hamasaki, Yuko
Okuda, Yusuke
Hamada, Riku
Ishikura, Kenji http://orcid.org/0000-0003-2692-6437
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (20FC1028)
Article History
Received: 24 July 2020
Revised: 2 May 2021
Accepted: 18 May 2021
First Online: 6 June 2021
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: K. Ishikura has received grants from Asahi Kasei Pharma Corporation; Chugai Pharmaceutical Co., Ltd.; Novartis International AG; Zenyaku Kogyo Co., Ltd.; Japan Blood Products Organization; Otsuka Pharmaceutical Co. Ltd.; Teijin Pharma Limited; Shionogi Co., Ltd.; Eisai Co., Ltd.; Astellas Pharma Inc.; and JCR Pharmaceuticals Co., Ltd. and lecture fees from Asahi Kasei Pharma Corporation; Chugai Pharmaceutical Co., Ltd.; Novartis International AG; Zenyaku Kogyo Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.; Alexion Pharmaceuticals Inc.; and Pfizer Inc. and consultant fees from Alexion Pharmaceuticals Inc. and Vifor Pharma Management Ltd. Y. Hamasaki belongs to a department endowed with sponsorship from Asahi Kasei Pharma Corporation, Novartis Pharma K.K., Chugai Pharmaceutical Co., and Astellas Pharma until 28 February 2018. Y. Hamasaki has received lecture fees and travel fees from Chugai Pharmaceutical Co., Novartis International AG, Alexion Pharmaceuticals Inc., and Pfizer Inc. R. Hamada has received grants from Chugai Pharmaceutical Co., Ltd.; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. and lecture fees from Alexion Pharmaceuticals, Inc.; Asahi Kasei Pharma Corporation; Teijin Pharma Ltd.; and Chugai Pharmaceutical Co., Ltd.